NCT00037791

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (planned)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of this investigational drug in the prevention of thrombocytopenia in patients with solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support.

Conditions

• Neoplasms
• Thrombocytopenia
• Multiple Myeloma
• Lymphoma, Malignant

Interventions

Type	Name	Description
DRUG	(PN-152,243)/PN-196,444

Timeline

• Start date: 1999-12-01
• Completion: 2002-09-01
• First posted: 2002-05-22
• Last updated: 2006-11-09

Locations

9 sites across 3 countries: United States, Argentina, Mexico